| Literature DB >> 35273053 |
Steven Wambua1, Lucas Malla2, George Mbevi2, Joel Kandiah3, Amen-Patrick Nwosu4, Timothy Tuti2, Chris Paton4, Bernard Wambu5, Mike English2,4, Emelda A Okiro6,4.
Abstract
OBJECTIVE: In this study, we assess the indirect impact of COVID-19 on utilisation of immunisation and outpatient services in Kenya.Entities:
Keywords: COVID-19; DHIS2; SARS-CoV-2; immunization; outpatient services
Mesh:
Year: 2022 PMID: 35273053 PMCID: PMC8914407 DOI: 10.1136/bmjopen-2021-055815
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Daily seven moving average trend of COVID-19 cases in Kenya showing various public health interventions initiated by the government to control the spread of the pandemic.
Description of indicators analysed in this study and Kenyan Ministry of Health (MOH) source forms used to capture the data
| Category | Description | Assigned names in this study | Source form |
| Immunisation | Bacillus Calmette-Guerin (BCG) vaccine doses administered | BCG | MOH 710 |
| Oral polio vaccine (OPV) doses administered | OPV dose 1, dose 2 and dose 3 | MOH 710 | |
| Rotavirus vaccine doses administered | Rotavirus dose 1 and dose 2 | MOH 710 | |
| Pneumococcal conjugate vaccine doses administered | Pneumococcal dose 1, dose 2 and dose 3 | MOH 710 | |
| Diphtheria, Tetanus, Pertussis (DPT) vaccine doses administered | DPT 1, 2 and 3 | MOH 710 | |
| Inactivated Polio Vaccine (IPV) doses administered | IPV | MOH 710 | |
| Measles vaccine doses administered | Measles dose 1 and dose 2 | MOH 710 | |
| Outpatient visits | Antenatal care (ANC) first visit | ANC 1 | MOH 711 |
| Antenatal care fourth visits | ANC 4 | MOH 711 | |
| Outpatient department (OPD) visits in under-fives | OPD <5 years | MOH 705A | |
| Outpatient department visits in over-fives | OPD >5 years | MOH 705B | |
| Outpatient department visits with pneumonia in under-fives | OPD pneumonia<5 years | MOH 705 A | |
| Outpatient department visits with pneumonia in over-fives | OPD pneumonia>5 years | MOH 705B | |
| No of new cases of diabetes | Diabetes new cases | MOH 705 A and B | |
| No of new plus revisits of diabetes cases | Diabetes total cases | MOH 705 A and B | |
| No of new hypertension cases | Hypertension new cases | MOH 705 A and B | |
| No of new plus revisits of hypertension cases | Hypertension total cases | MOH 705 A and B | |
| No of HIV tests performed | HIV tests performed | MOH 731 |
Segmented regression results showing rate ratios (RR) for COVID-19 intervention, time (pre-existing trend) and trend (post-COVID-19 trend)
| Covariate | OPD <5 years | OPD >5 years | OPD pneumonia <5 years | OPD pneumonia >5 years | ||||||||
|
|
|
|
|
|
|
|
| |||||
|
| 0.50 | (0.44 to 0.57) | <0.01 | 0.65 | (0.57 to 0.75) | <0.01 | 0.43 | (0.38 to 0.47) | <0.01 | 0.62 | (0.55 to 0.70) | <0.01 |
| | 1.00 | (0.99 to 1.01) | 0.15 | 1.00 | (1.00 to 1.01) | 0.02 | 1.01 | (1.00 to 1.01) | <0.01 | 1.00 | (0.99 to 1.01) | 0.05 |
| | 1.05 | (1.03 to 1.06) | <0.01 | 1.02 | (1.00 to 1.04) | 0.03 | 1.07 | (1.05 to 1.08) | <0.01 | 1.03 | (1.02 to 1.05) | <0.01 |
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
| ||||
|
| 0.96 | (0.83 to 1.10) | 0.55 | 0.86 | (0.80 to 0.93) | <0.01 | 1.17 | (0.89 to 1.52) | 0.25 | 0.95 | (0.93 to 0.97) | <0.01 |
| | 1.00 | (0.99 to 1.00) | 0.61 | 1.00 | (0.99 to 1.00) | 0.13 | 0.99 | (0.98 to 1.00) | 0.13 | 1.00 | (1.00 to 1.01) | <0.01 |
| | 1.01 | (0.99 to 1.03) | 0.12 | 1.00 | (0.99 to 1.01) | 0.90 | 0.99 | (0.97 to 1.01) | 0.57 | 1.00 | (1.00 to 1.00) | 0.05 |
|
|
|
| ||||||||||
|
|
|
|
|
|
|
| ||||||
|
| 0.87 | (0.75 to 1.00) | 0.05 | 0.89 | (0.82 to 0.96) | <0.01 | 0.97 | (0.94 to 0.99) | 0.01 | |||
| | 1.00 | (0.99 to 1.01) | 0.81 | 1.01 | (1.00 to 1.01) | <0.01 | 0.97 | (0.97 to 0.97) | <0.01 | |||
| | 1.00 | (0.99 to 1.01) | 0.59 | 1.00 | (0.99 to 1.01) | 0.90 | 1.01 | (1.00 to 1.01) | <0.01 | |||
The 95% CIs and p values are also show.
*Estimate after fitting ARMA model to indicator where autocorrelation was detected. The ARMA (p, q) parameters for ANC 1 are (1,0) and (2,0) for HIV tests performed.
ANC, antenatal care; ARMA, autoregressive moving average; OPD, outpatient department.
Figure 2Temporal trends in monthly immunisation and outpatient attendance nationally and by year. ANC, antenatal care; OPD, outpatient department;BCG, Bacillus Calmette–Guérin vaccine; OPV, Oral polio vaccine;DPT, Diphtheria, Tetanus, Pertussis vaccine; IPV, Inactivated Polio Vaccine
Figure 3Statistical process control chart of immunisation, antenatal care (ANC) and outpatient services. Horizontal dashed lines represent the 3 SD mark. OPD, outpatient department;BCG, Bacillus Calmette–Guérin vaccine; OPV, Oral polio vaccine;DPT, Diphtheria, Tetanus, Pertussis vaccine; IPV, Inactivated Polio Vaccine
Figure 4Fitted lines of interrupted time series models for outpatient and antenatal care attendance. vertical lines represent the month (March 2020) COVID-19 was announced in Kenya and as a pandemic by the WHO. ANC, antenatal care; OPD, outpatient department.